- Home
- FORA vs MIST Comparison
FORA vs MIST Comparison
Compare FORA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- MIST
- Stock Information
- Founded
- FORA 2014
- MIST 2003
- Country
- FORA United States
- MIST Canada
- Employees
- FORA N/A
- MIST N/A
- Industry
- FORA Computer Software: Prepackaged Software
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- MIST Health Care
- Exchange
- FORA Nasdaq
- MIST Nasdaq
- Market Cap
- FORA 62.7M
- MIST 53.9M
- IPO Year
- FORA N/A
- MIST N/A
- Fundamental
- Price
- FORA $1.88
- MIST $1.11
- Analyst Decision
- FORA Strong Buy
- MIST Strong Buy
- Analyst Count
- FORA 1
- MIST 2
- Target Price
- FORA $5.00
- MIST $9.50
- AVG Volume (30 Days)
- FORA 19.3K
- MIST 1.6M
- Earning Date
- FORA 05-16-2025
- MIST 05-20-2025
- Dividend Yield
- FORA N/A
- MIST N/A
- EPS Growth
- FORA N/A
- MIST N/A
- EPS
- FORA N/A
- MIST N/A
- Revenue
- FORA $20,153,263.00
- MIST N/A
- Revenue This Year
- FORA $13.31
- MIST N/A
- Revenue Next Year
- FORA N/A
- MIST N/A
- P/E Ratio
- FORA N/A
- MIST N/A
- Revenue Growth
- FORA N/A
- MIST N/A
- 52 Week Low
- FORA $1.85
- MIST $0.63
- 52 Week High
- FORA $4.03
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- FORA 43.10
- MIST 43.96
- Support Level
- FORA $1.93
- MIST $1.28
- Resistance Level
- FORA $2.02
- MIST $1.32
- Average True Range (ATR)
- FORA 0.13
- MIST 0.12
- MACD
- FORA -0.00
- MIST 0.02
- Stochastic Oscillator
- FORA 6.60
- MIST 27.39
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).